Price
No data yet.
Social Signal Score
Revenue
$5.0K-58.24%Company Profile
- CEO
- James Keener
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 1
- Beta
- 1.19
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -274.08
Financials
Revenue
$5.0K-58.2%Net Income
$150.1KEBITDA
$-195.7KFree Cash Flow
$111.5K+843.9%EPS (diluted)
$0.01Shares Outstanding (diluted)
14.19M+14913.0%Operating Expenses
$199.9KCash & Debt
$29.2KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $18.3K | $-1.56M | $-0.15 |
| 2024 | $12.7K | $-899.0K | $-0.11 |
| 2023 | $28.6K | $-712.0K | $-0.12 |
| 2022 | $17.2K | $-896.0K | $-1.27 |
| 2021 | $19.8K | $-1.05M | $-4.67 |
| 2020 | $16.3K | $-847.0K | $-6.23 |
| 2019 | $9.9K | $-239.0K | $-1.92 |
| 2018 | $0.00 | $-1.41M | $-12.43 |
| 2017 | $0.00 | $-62.5K | $-0.67 |
| 2016 | $19.0K | $-171.3K | $-1.84 |
| 2015 | $0.00 | $-227.4K | $-2.68 |
| 2014 | $0.00 | $-2.58M | $-30.97 |
| 2013 | $0.00 | $-18.3K | $-0.26 |
Valuation
BDPThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsaccessnewswire.com·12d ago·Neutral
…e formula fits into his preparation for live broadcasts, commentary, and podcasting. LAS VEGAS, NV / ACCESS Newswire / September 23, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of science-driven wellness formulations, today highlighted a new Instagram video featuring UFC Hall of Famer and former UFC middleweight champion Michael Bisping, who serves as a paid brand ambassador for the company's Xcellara™ and MyndSystem™ platform.
View source ↗ - Newsaccessnewswire.com·32d ago·Neutral
…ch and highlights the retirement of major convertible debt and 43.25M insider shares. LAS VEGAS, NV / ACCESS Newswire / September 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of science-driven human renewal formulations, today announced that the first commercial orders for XcellaraHeart™ will ship next week.
View source ↗ - Newsaccessnewswire.com·36d ago·Neutral
…ll help promote MyndSystem™ as part of a disciplined day-and-night performance routine LAS VEGAS, NV / ACCESS Newswire / August 31, 2026 / BioAdaptives®, Inc. (OTCID:BDPT) announced today that UFC Hall of Famer and former UFC middleweight champion Michael Bisping has joined MyndSystem™ as a paid brand ambassador. The partnership will focus on promoting MyndMed™ and MyndRenew™, the products at the core of the MyndSystem™ platform.
View source ↗ - Newsaccessnewswire.com·54d ago·Positive
BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT) announced a shareholder update on its current capital restructuring, adjustments in executive equity, and long-term operational strategies.
View source ↗ - Newsaccessnewswire.com·55d ago·Neutral
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks. LAS VEGAS, NV / ACCESS Newswire / August 12, 2026 / BioAdaptives, Inc. (OTCID:BDPT) announced the official commercial launch and pre-order avai
View source ↗
Insider trading
Open-market buys and sells by BDPT officers and directors.
- Bought
- $21k
- Sold
- $40k
5 trades
1 trade
- Frissora Mark Pbought
- Frissora Mark Pbought
- Dissanayake Gimhana Sasankabought
- Ferris Holding Inc.bought
- Epling Barrybought
- Chiang Richardsold
25 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BDPT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.